Lecithin-Modified Calcium Phosphate Nanoparticles for Bisphosphonate Uptake
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing bisphosphonate formulations, such as those containing alendronate, suffer from low bioavailability and significant side effects when administered orally, necessitating improved formulations with enhanced cellular uptake and reduced gastrointestinal risks.
Innovation Solution
Formulation of lecithin-modified calcium phosphate nanoparticles, particularly hydroxyapatite, encapsulating bisphosphonates like alendronate or zoledronate, with a size less than 200 nm and up to 40% mass content, prepared via a continuous reactor process to enhance cellular uptake and bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If oral administration of bisphosphonates is used, then the drug can be administered orally, but bioavailability is very low (below 1%) and side effects in the upper gastrointestinal tract occur
Solution Approach 1:
The patent uses hydroxyapatite nanoparticles as an intermediary carrier system. The nanoparticles serve as a mediator that enhances the bioavailability of bisphosphonates by improving their absorption while reducing gastrointestinal side effects. The nanoparticles facilitate drug transport across the gastrointestinal barrier, resolving the contradiction between ease of oral administration and low bioavailability.
Solution Approach 2:
The patent modifies the physical and chemical parameters of the bisphosphonate formulation by incorporating it into hydroxyapatite nanoparticles with specific size (less than 200 nm) and composition ratios (bisphosphonate content of 1-50 wt%). This parameter change transforms the drug delivery system to enhance absorption and reduce toxicity, thereby improving bioavailability while maintaining oral administration feasibility.
2Reliability
If hydroxyapatite nanoparticles are used as carrier, then cellular uptake is enhanced, but manufacturing complexity increases
Solution Approach 1:
The patent employs preliminary action by pre-modifying the surface of hydroxyapatite nanoparticles with lecithin before incorporating the bisphosphonate drug. This preliminary surface modification enhances cellular uptake and biocompatibility. The lecithin coating is applied in advance to the nanoparticle surface, creating a biocompatible interface that facilitates subsequent drug loading and cellular absorption, thereby resolving the contradiction between enhanced cellular uptake and manufacturing complexity.
3Object-affected harmful factors
If lecithin modification is applied to hydroxyapatite nanoparticles, then biocompatibility and cellular uptake are enhanced, but preparation process complexity increases
Solution Approach 1:
The patent uses lecithin as an intermediary modifying agent that coats the hydroxyapatite nanoparticle surface. This intermediary substance enhances biocompatibility and cellular uptake by creating a biocompatible interface between the nanoparticles and biological systems. The lecithin modification process, while adding some complexity, significantly improves the biological performance of the nanoparticles, resolving the contradiction between biocompatibility enhancement and preparation process complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The lecithin-modified nanoparticles demonstrate increased cellular uptake and bioavailability, reducing side effects and improving therapeutic efficacy.
Implementation Method 1
lecithin-modified calcium phosphate nanoparticles
Implementation Method 2
encapsulating bisphosphonates like alendronate or zoledronate
Implementation Method 3
enhanced cellular uptake
Data Source
AI summary
Formulation of nanoparticles of calcium phosphate, preferably hydroxyapatite, said nanoparticles being modified with lecithin, preferably phosphatidylcholine, said formulation having an enhanced cellular uptake and being a carrier for bisphosphonate, characterised in that bisphosphonate is selected from the group of bisphosphonate drugs approved for medical use, the group comprising alendronate and zoledronate, bisphosphonate is encapsulated in calcium phosphate nanoparticles in an amount up to 40% by mass, and the nanoparticles are less than 200 mn in size. Method of obtaining said formulation, comprising the steps: a. dissolving Ca(N03)2. 4H2O in a lecithin solution, b. dissolving (NH4)2HP04 in a bisphosphonate solution, c. adjusting the pH of the solution resulting from step a. and of the solution resulting from step b. to the value of 10, d. mixing the solutions from step c. in a reactor to obtain a suspension, e. centrifuging the suspension from step d. to obtain precipitate, f. purifying the precipitate from step e. by rinsing it four times with ultrapure water and centrifuging, g. drying the precipitate from step f. at 50° C. for 12-24 h, h. grinding the precipitate from step g. in a ball mill for 10 minutes at a speed of 150 rpm, wherein step d. is carried out in a continuous or batch reactor.